^
Association details:
| Biomarker: | FGFR mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug Class: | FGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials.
Published date:
05/13/2020
Excerpt:
We retrospectively analyzed medical records of patients with mUC who received an investigational therapy at the phase 1 clinic...Patients harboring a TP53 alt, compared to no alt, had a shorter median PFS of 3.2m vs 9.6 m (HR = 2.738 [1.247 - 6.011], p = 0.0121). On the contrary, median PFS was longer in FGFR alt, compared to no alt, 6.3m vs 3.2m (HR = 0.4662 [0.224 - 0.971], p = 0.0415).
DOI:
10.1200/JCO.2020.38.15_suppl.5029
